प्राथमिक स्रोत रिकॉर्ड
The company now guides for top-line data from the DECLARATION and LIBERTY Phase 3 studies of VYD2311 around the end of Q3 2026. Upon readout, Invivyd plans to either fully unblind and file a traditional BLA or partially unblind and file for Accelerated Approval based on antiviral activity and safety, with a confirmatory cohort post-approval.
EX-99.1 3 ivvd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY • Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy • Ajay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent Director • Ian Sheffield appointed to Invivyd’s Board of Directors as an independent director • DECLARATION and LIBERTY studies of VYD2311 approaching completion with further updates expected within weeks NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, cur
इनविविड ने एमआरएनए कोविड वैक्सीन के मुकाबले VYD2311 का LIBERTY फेज 3 परीक्षण शुरू किया
इनविविड ने वीवाईडी2311 के अपसाइज्ड फेज 3 डिक्लेरेशन ट्रायल में नामांकन पूरा किया
Invivyd ने DECLARATION परीक्षण का आकार बढ़ाया; VYD2311 टॉपलाइन अब Q3 2026 में
Invivyd: FDA ने VYD2311 चरण 3 COVID रोकथाम कार्यक्रम के लिए IND को मंजूरी दी